Download PDF
Kinder- und Jugendmedizin 2010; 10(04): 234-237
DOI: 10.1055/s-0038-1628979
Epilepsie
Schattauer GmbH

Stiripentol, Eslicarbazepinacetat & Co.

Die neuesten AntiepileptikaStiripentol, eslicarbacepine acetate & Co.The newest antiepileptic drugs
M. K. Bernhard
1   Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig
,
M. Landgraf
1   Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig
,
S. Syrbe
1   Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig
,
A. Merkenschlager
1   Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig
› Author Affiliations
Further Information

Publication History

Eingegangen am: 05 January 2010

angenommen am: 15 January 2010

Publication Date:
27 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

In den vergangenen sechs Jahren wurden in Deutschland sechs neue Antikonvulsiva zugelassen: Pregabalin, Rufinamid, Zonisamid, Lacosamid, Stiripentol und Eslicarbazepin-acetat. Teilweise handelt es sich um Substanzen, die über neue Mechanismen ihre erregungshemmende Wirkung entfalten, teilweise um die Weiterentwicklung bestehender Antikonvulsiva. Diese neuen Medikamente sind bislang entweder nur bei Erwachsenen oder als sogenannte Orphan Drugs nur sehr eingeschränkt zugelassen.

Im Folgenden werden die genannten neuen Antikonvulsiva hinsichtlich ihrer Zulassungen, Wirkmechanismen und Nebenwirkungsprofile kurz charakterisiert. Die vor allem für Kinder und Jugendliche relevanten bisherigen Studiendaten werden genannt.

Diese neuesten Antikonvulsiva dürften vor allem als Zusatztherapie auch in der Pädiatrie künftig vielversprechende Therapieoptionen bieten.

Summary

Six new antiepileptic drugs have been developed in the recent six years: pregabalin, rufinamide, zonisamide, lacosamide, stiripentol and eslicarbazepine acetate. Partly, they are drugs that act via new mechanisms of excitation inhibition; partly, they are further developments of existing antiepileptic drugs. They are either approved for adults or as so-called orphan drugs for children.

In the following the new antiepileptic drugs mentioned above are characterized concerning their approval, mechanisms of action and adverse effects. The main studies especially with children and adolescents are reported. Hopefully these new antiepileptic drugs will offer positive therapeutical options as add-on drugs in pediatric patients.

Schlüsselwörter

Orphan Drug - Pregabalin - Rufinamid - Zonisamid - Lacosamid - Stiripentol - Eslicarbazepinacetat

Keywords

Orphan drug - pregabalin - rufinamide - zonisamide - lacosamide - stiripentol - eslicarbazepine acetate
 

  • Literatur

  • 1 Aldenkamp AP, Alpherts WCJ. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006; 47: 1153-1159.
    CrossrefPubMedGoogle Scholar
  • 2 Almeida L, Minciu I, Nunes T. et al. Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy. J Clin Pharmacol 2008; 48: 966-977.
    CrossrefPubMedGoogle Scholar
  • 3 Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007; 4: 88-96.
    CrossrefPubMedGoogle Scholar
  • 4 Arain AM. Pregablin in the management of partial epilepsy. Neuropsychiatr Dis Treat 2009; 5: 407-413.
    PubMedGoogle Scholar
  • 5 Arroyo S. Rufinamide. Neurotherapeutics 2007; 4: 155-162.
    CrossrefPubMedGoogle Scholar
  • 6 Biton V, Rosenfeld WE, Whitesides J. et al. Intravenous lacoamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-424.
    CrossrefPubMedGoogle Scholar
  • 7 Brodie MJ, Rosenfeld WE, Vazquez B. et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebocontrolled trial. Epilepsia 2009; 50: 1899-1909.
    CrossrefPubMedGoogle Scholar
  • 8 Camfield CS, Camfield PR, Gordon K. et al. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. Epilepsia 1996; 37: 19-23.
    CrossrefPubMedGoogle Scholar
  • 9 Cross SA, Curran MP. Lacosamide: in partial-onset seizures. Drugs 2009; 69: 449-459.
    CrossrefPubMedGoogle Scholar
  • 10 Desitin Arzneimittel GmbH, Hamburg, Fachinformation Diacomit®, Stand Dezember 2007
  • 11 Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 2007; 4: 145-148.
    CrossrefPubMedGoogle Scholar
  • 12 Elger C, Halasz P, Maia J. et al. BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebocontrolled, parallelgroup phase III study. Epilepsia 2009; 50: 454-463.
    PubMedGoogle Scholar
  • 13 Esai Arzneimittel Ltd. United Kingdom, Fachinformation Inovelon®, Stand März 2009
  • 14 Esai Arzneimittel Ltd. United Kingdom, Fachinformation Zonegran®, Stand Juli 2009
  • 15 Harris JA, Murphy JA. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009; 43: 1809-1817.
    CrossrefPubMedGoogle Scholar
  • 16 Gil-Nagel A, Lopes-Lima J, Almeida L. et al. BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-287.
    PubMedGoogle Scholar
  • 17 Hughes JR. Absence seizures: a review of recent reports with new concepts. Epilepsy Behav 2009; 15: 404-412.
    CrossrefPubMedGoogle Scholar
  • 18 Inoue Y, Ohtsuka Y, Oguni H. et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009; 50: 2362-2368.
    CrossrefPubMedGoogle Scholar
  • 19 Jan MMS, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractabale childhood epilepsy. Ped Neurol 2009; 40: 347-350.
    CrossrefPubMedGoogle Scholar
  • 20 Kamel JT, D’Souza WJ, Cook MJ. Severe and disabling constipation: An adverse effect of pregabalin. Epilepsia. 2009 Oct 20 (Epub ahead of print)
    PubMedGoogle Scholar
  • 21 Kassai B, Chiron C, Augier S. et al. Severe myoclonic epilepsy in infancy: A systematic review and a metaanalysis of individual patient data. Epilepsia 2008; 49: 343-348.
    CrossrefPubMedGoogle Scholar
  • 22 Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of firstline therapy. Epilepsy Behav 2009; 14: 429-431.
    CrossrefPubMedGoogle Scholar
  • 23 Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005; 20: 212-219.
    CrossrefPubMedGoogle Scholar
  • 24 Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paeditr Neurol 2008; 7: 19-23.
    Google Scholar
  • 25 Lee YJ, Kang HC, Seo JH. et al. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev 2010; 32 (03) 208-212.
    CrossrefPubMedGoogle Scholar
  • 26 Leitlinien für Diagnostik und Therapie in der Neurologie. 4. Aufl. Stuttgart: Georg Thieme Verlag; 2008. ; 654ff.
    Google Scholar
  • 27 Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008; 23 (01) CD005612.
    Google Scholar
  • 28 Pfizer, Fachinformation Lyrica Hartkapseln®, Stand August 2009
  • 29 Quilichini P, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 2006; 47: 704-716.
    CrossrefPubMedGoogle Scholar
  • 30 Schweizer S, Kuhn K. Stiripentol (Diacomit®) - eine neue Therapieoption zur Behandlung des Dravet- Syndroms (SMEI). Z Epileptol 2008; 21: 135-141.
    CrossrefGoogle Scholar
  • 31 Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-294.
    CrossrefPubMedGoogle Scholar
  • 32 Shinnar S, Pellock JM, Conry JA. Open-label, longterm safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009; 13: 3-9.
    CrossrefPubMedGoogle Scholar
  • 33 Steinhoff BJ. Die Expertenfrage. Z Epileptol 2008; 21: 156-157.
    CrossrefGoogle Scholar
  • 34 Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010; 19 (01) 31-35.
    CrossrefPubMedGoogle Scholar
  • 35 Trojnar MK, Wojta K, Trojnar MP. et al. Stiripentol. A novel antiepileptic drug. Pharmacol Reports 2005; 57: 154-160.
    Google Scholar
  • 36 Tsao CY. Current trends in the treatment of infantile spasms. Neuropsychiatr Dis Treat 2009; 5: 289-299.
    PubMedGoogle Scholar
  • 37 Wheless JW, Conry J, Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24: 1520-1525.
    CrossrefPubMedGoogle Scholar